Your browser doesn't support javascript.
loading
Synchronous plasma cell neoplasm and B lymphoblastic leukemia/lymphoma at initial presentation: first report of an unusual association with a good outcome.
Perez, Ivette; Schinke, Carolina; Pina-Oviedo, Sergio; Alapat, Daisy.
Afiliação
  • Perez I; Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Schinke C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Pina-Oviedo S; Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR, USA. SPinaoviedo@uams.edu.
  • Alapat D; Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, 4301 W. Markham St. # 502, Little Rock, AR, 72205, USA. SPinaoviedo@uams.edu.
J Hematop ; 15(1): 29-34, 2022 Mar.
Article em En | MEDLINE | ID: mdl-38358598
ABSTRACT
A synchronous diagnosis of a plasma cell neoplasm (PCN) and a non-plasma cell hematologic malignancy is very rare. We report what we believe is the first instance of a synchronous PCN and B lymphoblastic leukemia/lymphoma (B-ALL) diagnosed at initial presentation. The patient underwent laboratory evaluation for an underlying plasma cell neoplasm, including immunology studies, bone marrow biopsy, and flow cytometry immunophenotyping. Serum lambda free light chain and serum IgG were elevated, with an IgG lambda M-protein identified by serum protein electrophoresis and immunofixation. The clinical working diagnosis was plasma cell myeloma. Bone marrow biopsy was positive for a composite PCN and B-ALL. The patient received treatment with VDT-PACE chemotherapy followed by autologous stem cell transplant and maintenance therapy with bortezomib/daratumumab and is in complete remission for both diseases 3.5 years after diagnosis. This case not only adds to the known repertoire of hematologic neoplasms that can occur in association to a PCN, but also demonstrates that patients presenting with this rare combination of hematopoietic neoplasms can be effectively treated simultaneously with excellent responses. Additional research is warranted to understand the pathophysiology, to identify potential prognostic factors, and to develop specific therapeutic plans for these patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Hematop Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Hematop Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos